Clinical trials: pMN
Infertility
Effects of Embryogen in RIF Patients
The purpose of this study was to investigate the potential effects of Granulocyte-Macrophage Stimulating-Colony Factor (GM-CSF) supplementation in embryo culture for patients with repeated implantation failure (RIF)
- Trial name
- RIF (NCT02250768)
- Testing
- GM-CSF
- Where
- 2 sites in Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vietnam National University
Lymphoma, Non-Hodgkin, HIV Infections
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide…
- Trial name
- NCT00000801
- Testing
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infertility
Diafert for Embryo Selection and Fertility Improvement
Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.
- Trial name
- DESTINy (NCT02586272)
- Testing
- Daifert, Control Group
- Where
- Belgium
- Volunteers
- 61 people
- Sponsor
- Forest Laboratories
Asthma
Clinical Study of Relationship Between Granulocyte Activation, HDAC2 and Severe Asthma
Program： Clinical Study of Relationship Between Granulocyte Activation, HDAC2 and Severe Asthma Aim：The early prediction of severe asthma, early intervention on the disease, reduce the family and the national finance.
- Trial name
- NCT02881502
- Testing
- severe asthma group
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
HIV Infections, Cytopenias
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
To evaluate the safety, tolerance and biological activity of filgrastim (granulocyte colony-stimulating factor; G-CSF) given by daily subcutaneous (SC) injection prior to and concomitantly with erythropoietin (EPO) and zidovudine…
- Trial name
- NCT00002281
- Testing
- Filgrastim, Epoetin alfa, Zidovudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Amgen
Acne Scars - Atrophic, Wound Healing
Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars.
Atrophic acne scars (AAS) is one of the most common skin sequelae following acne vulgaris. Fractional laser has shown great therapeutic potential in recent years, while there is no standard of wound care after laser resurfacing.
- Trial name
- NCT07305675
- Testing
- rhGM-CSF-containing gel, 1927-nm TFL
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Multiple Myeloma, Lymphoma
A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
Hematopoietic stem cells (HSC) are used to support the administration of high dose chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5 million HSC per kilogram are required.
- Trial name
- NCT00234169
- Testing
- VTP195183
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Recurrent Osteosarcoma
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the…
- Trial name
- NCT02502786
- Testing
- humanized anti-GD2 antibody, GM-CSF
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Colony Stimulating Factors
Long-acting G-CSF for Febrile Neutropenia
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Colony Stimulating Factors, Febrile Neutropenia, Myelosuppression Adult
- Trial name
- NCT03740464
- Testing
- long-acting granulocyte colony stimulating factor, Short-term granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Lei Li
Peripheral Vascular Diseases, Ischemia
Autologous Transplantation of Bone Marrow Mononuclear Cell (BM-MNC) With and Without Granulocyte-Colony Stimulation Factor (G-CSF) for Treatment of Chronic Lower Limb Ischemic Patients
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of mononuclear cells with and without G-CSF in patients with chronic lower limb ischemia.
- Trial name
- NCT00677404
- Testing
- BM-MNC injection
- Where
- 2 sites in Iran
- Volunteers
- 20 people
- Sponsor
- Royan Institute
Infertility
Diafert for Embryo Selection and Fertility Improvement (DESTINy)
Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.
- Trial name
- DESTINy (NCT02593513)
- Testing
- Daifert, Control Group
- Where
- Hungary
- Volunteers
- 108 people
- Sponsor
- Forest Laboratories
Thyroid Cancer, Thyroid Nodule
Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy
Thyroid surgery is the most common surgical procedure among endocrine surgeries. It is performed in patients with suspected malignancy, patients diagnosed with malignancy, and for toxic nodular goiter [1].
- Conditions
- Thyroid Cancer, Thyroid Nodule, Thyroid Diseases, Delta Neutrophyl Index
- Trial name
- NCT04425512
- Testing
- Complete Blood Count
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Ewing's Sarcoma, Rhabdomyosarcoma
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
Filgrastim (granulocyte colony-stimulating factor), which is administered by daily subcutaneous injection after cytotoxic chemotherapy, shortens the duration of chemotherapy-induced neutropenia and lowers the risk of infection.
- Conditions
- Ewing's Sarcoma, Rhabdomyosarcoma, MPNST, Synovial Sarcoma
- Trial name
- NCT00004853
- Testing
- Filgrastim, Filgrastim-SD/01
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Diamond Blackfan Anemia
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)
Gene therapy is a new possible treatment for the anemia of DBAS. Gene therapy will soon be available for patients with RPS19-mutated DBAS.
- Trial name
- NCT07186179
- Testing
- Mobilization Regimen
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Viral Infection, Sepsis
COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit
Patient admitted in intensive care unit (ICU) for acute infection whether it be viral or bacterial had major impairment of the immune response.
- Trial name
- COMPACT (NCT05671159)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Limoges
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Atherosclerosis, Cardiovascular Diseases
Semaglutide and Vascular Regeneration
SEMA-VR is a prospective, randomized, 6-month long, open-label study of semaglutide. Approximately 100 participants with type 2 diabetes and/or obesity will be randomized (1:1) to receive semaglutide at escalating doses (up to…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
- Trial name
- SEMA-VR (NCT05870462)
- Testing
- Semaglutide Pen Injector
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
Acute on Chronic Liver Failure
Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF
The purpose of the study is to determine whether Granulocyte Colony Stimulating factor(G-CSF) therapy is effective in the treatment of patients with Acute on chronic liver failure(ACLF).
- Trial name
- NCT01036932
- Testing
- Granulocyte Colony Stimulating Factor, Normal Saline
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Govind Ballabh Pant Hospital
Infertility
Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF
This study is to assess whether addition of 2 ng/ml GM-CSF into a specific culture medium will increase the chance of a pregnancy after in vitro fertilisation.
- Trial name
- GM-CSF (NCT00565747)
- Testing
- Test culture, Control culture
- Where
- 14 sites in Denmark, Sweden
- Volunteers
- 1,332 people
- Sponsor
- Origio A/S
Multiple Myeloma
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
- Trial name
- NCT00948922
- Testing
- Bortezomib, Melphalan, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute